Skip to main navigation Skip to search Skip to main content

Translocation of lysophosphatidic acid phosphatase in response to gonadotropin-releasing hormone to the plasma membrane in ovarian cancer cell

  • Wen Shu Sun
  • , Atsushi Imai
  • , Michiyo Sugiyama
  • , Tatsuro Furui
  • , Teruhiko Tamaya
  • , Masanao Saio
  • , Andrew J. Morris

Research output: Contribution to journalArticlepeer-review

8 Scopus citations

Abstract

Objective Lysophosphatidic acid mediates proliferative and/or morphologic effects on multiple cell lineages, which include ovarian cancer cells. Lysophosphatidic acid hydrolysis limits the duration of lysophosphatidic acid's action. We examined hormonal translocation of lipid phosphate phosphatase type 3 to the plasma membrane in gonadotropin-releasing hormone-responsive ovarian cancers. Study design Ovarian cancers that were removed surgically and the ovarian cancer cell lines Caov-3 and SK-OV-3 were examined. Lipid phosphate phosphatase type 3 protein and activity in plasma membranes were assessed by immunohistochemical staining with lipid phosphate phosphatase type 3-specific antibodies and by the measurement of the conversion of exogenous [ 3H-oleoyl]lysophosphatidic acid to mono[ 3H-oleoyl] glycerol, respectively. Results In ovarian cancers that were removed surgically, the cell surface staining and activity measurements indicated that a portion of the enzyme was localized to the plasma membrane. In Caov-3 cells and SK-OV-3 cells, lipid phosphate phosphatase type 3 protein was present both in the cytoplasm and at the plasma membrane. Treatment of the cells with a gonadotropin-releasing hormone agonist buserelin produced a rapid and progressive translocation of lipid phosphate phosphatase type 3 protein to the plasma membrane, with a concomitant loss of cytoplasmic staining. The enzyme activity in plasma membrane was also increased when the cell lines were exposed to the gonadotropin-releasing hormone agonist in intact cells before the assay of the cell membranes. Conclusion These findings support the presence of lipid phosphate phosphatase type 3 in plasma membrane of ovarian cancers and provide for the ability of agonists (such as gonadotropin-releasing hormone) to induce the translocation of lipid phosphate phosphatase type 3 to plasma membrane in ovarian cancer cells.

Original languageEnglish
Pages (from-to)143-149
Number of pages7
JournalAmerican Journal of Obstetrics and Gynecology
Volume191
Issue number1
DOIs
StatePublished - Jul 2004

Bibliographical note

Funding Information:
Supported in part by research grants (#12470340 and #14770844) from the Ministry of Education, Culture and Science, Japan.

Funding

Supported in part by research grants (#12470340 and #14770844) from the Ministry of Education, Culture and Science, Japan.

Funders
Ministerie van Onderwijs, Cultuur en Wetenschap

    UN SDGs

    This output contributes to the following UN Sustainable Development Goals (SDGs)

    1. SDG 3 - Good Health and Well-being
      SDG 3 Good Health and Well-being

    Keywords

    • Antiproliferative action
    • Gonadotropin-releasing hormone
    • Lysophosphatidic acid
    • Ovarian cancer
    • Phosphatase

    ASJC Scopus subject areas

    • Obstetrics and Gynecology

    Fingerprint

    Dive into the research topics of 'Translocation of lysophosphatidic acid phosphatase in response to gonadotropin-releasing hormone to the plasma membrane in ovarian cancer cell'. Together they form a unique fingerprint.

    Cite this